Dupilumab (open-label) ( DrugBank: Dupilumab )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
98 | 好酸球性消化管疾患 | 1 |
98. 好酸球性消化管疾患
臨床試験数 : 171 / 薬物数 : 184 - (DrugBank : 47) / 標的遺伝子数 : 42 - 標的パスウェイ数 : 141
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03678545 (ClinicalTrials.gov) | May 14, 2021 | 6/8/2018 | Dupilumab in Eosinophilic Gastritis | A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Dupilumab (Anti-IL4a) in Subjects With Eosinophilic Gastritis | Eosinophilic Gastritis;Eosinophilic Gastroenteritis | Drug: Dupilumab (blinded);Drug: Placebo (blinded);Drug: Dupilumab (open-label) | Children's Hospital Medical Center, Cincinnati | Regeneron Pharmaceuticals;National Institutes of Health (NIH) | Recruiting | 12 Years | 70 Years | All | 40 | Phase 2 | United States |